Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 3Phase 1 3Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 3Vitamin D Deficiency 1Smoldering Multiple Myeloma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1POEMS Syndrome 1Neuroblastoma 1Neoplasms, Plasma Cell 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Leukemia-Lymphoma, Adult T-Cell 1Immunoblastic Lymphadenopathy 1

Interventions

pembrolizumab 1Lenalidomide 1Leflunomide 1Immunotherapy, Active 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Smoldering Multiple Myeloma × Lenalidomide × Clear all
NCT03631043 2025-12-19

Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Completed
30 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡